Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending October 2011. The report details a specific share repurchase transaction executed on October 3, 2011, pursuant to shareholder authority granted at the Annual General Meeting on May 5, 2011.
Key Financial Metrics
The filing does not provide data on revenue, profit, cash flow, margins, debt, or liquidity. It focuses exclusively on capital structure and share repurchase activity.
- Shares Purchased: 400,000 Ordinary shares of 25 pence each.
- Purchase Price Range: High of 1,327 pence per share; Low of 1,308 pence per share.
- Treasury Shares Held: 505,396,816 shares (9.07% of total issued share capital).
- Treasury Shares (Including Unsettled): 505,796,816 shares (9.99% of current total voting rights).
- Shares in Issue (Excluding Treasury): 5,064,601,765 shares.
Material Changes
The primary material change reported is the reduction of outstanding shares through the purchase of 400,000 shares for Treasury. Consequently, the percentage of total voting rights held in Treasury increased to 9.99% when including unsettled purchases. The filing does not provide comparative financial data to assess changes in operational performance versus prior periods.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, or outlook for future periods. It includes a standard disclaimer stating the announcement does not constitute an offer or solicitation to purchase securities and confirms conformity with the Financial Services Authority's Disclosure and Transparency Rules.
Investor Verification Checklist
- Verify the total cost of the 400,000 share repurchase based on the weighted average price between 1,308 and 1,327 pence.
- Confirm the impact of the 9.99% Treasury holding on the denominator for shareholder notification thresholds under Disclosure and Transparency Rules.
- Check subsequent filings for the settlement status of the 400,000 shares mentioned as "purchased but not yet settled."
- Note that this filing does not contain operational financial results; refer to Form 20-F or quarterly reports for revenue and earnings data.